- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
- EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)
- EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
- EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
- EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
- EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
- EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
- EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
More ▼
Key statistics
On Tuesday, MorphoSys AG (MOR:NSQ) closed at 4.04, 27.44% above the 52 week low of 3.17 set on Dec 28, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.95 |
---|---|
High | 4.05 |
Low | 3.95 |
Bid | 1.62 |
Offer | 5.50 |
Previous close | 3.97 |
Average volume | 127.27k |
---|---|
Shares outstanding | 136.93m |
Free float | 134.65m |
P/E (TTM) | -- |
Market cap | 539.20m USD |
EPS (TTM) | -1.19 USD |
Data delayed at least 15 minutes, as of Mar 28 2023 20:59 BST.
More ▼